Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Apex Biotechnology Corp. (1733.TW)
Hsinchu City, TW
Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup features a variety of personal health monitoring systems, including those for tracking blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1c, and ketone levels. In addition, the company provides self-testing solutions for coagulation and multi-parameter analysis, alongside advanced hemoglobin screening systems. Beyond patient diagnostics, Apex Biotech also offers systems for detecting pesticide residues. The company further extends its services to include digital care management and telehealth platforms. Established in 1997, Apex Biotechnology Corp. operates from its headquarters located in Hsinchu City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.53% | +0.71% | -3.57% | -7.79% | -13.41% | -6.73% | -7.64% | +5.38% | +20.59% | -39.45% | +9.31% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+5.0% ★ Q1'26: -7.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+28.4% Q1'26: +30.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+5.5% Q1'26: +14.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+7.2% ★ Q1'26: +16.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+8.8% ★ Q1'26: +23.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.4% ★ Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.74× ★ Q1'26: 0.43× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.85B
est: 1.89B (-2.3%)
|
1.76B
est: 2.04B (-13.6%)
|
1.80B
est: 1.79B (+0.3%)
|
2.04B
est: 2.04B (0.0%)
|
2.20B
est: 2.17B (+1.1%)
|
2.01B
est: 2.16B (-7.2%)
|
2.13B
est: 2.10B (+1.5%)
|
2.24B
est: 2.31B (-2.8%)
|
1.68B
est: 2.29B (-26.8%)
|
1.85B
est: 1.89B (-2.1%)
|
1.94B
est: 11.59B (-83.2%)
|
12.55B
12.55B – 12.55B
+8.3% YoY
|
| EBITDA |
434.40M
est: 239.40M (+81.5%)
|
163.45M
est: 258.60M (-36.8%)
|
230.89M
est: 226.68M (+1.9%)
|
278.35M
est: 258.85M (+7.5%)
|
289.10M
est: 275.40M (+5.0%)
|
225.73M
est: 273.54M (-17.5%)
|
289.65M
est: 265.94M (+8.9%)
|
299.07M
est: 292.53M (+2.2%)
|
221.06M
est: 290.00M (-23.8%)
|
221.58M
est: 236.11M (-6.2%)
|
201.65M
est: 1.45B (-86.1%)
|
1.57B
1.57B – 1.57B
+8.3% YoY
|
| EBIT |
300.80M
est: 156.44M (+92.3%)
|
245.89M
est: 168.98M (+45.5%)
|
161.00M
est: 148.13M (+8.7%)
|
172.46M
est: 169.15M (+2.0%)
|
172.57M
est: 179.96M (-4.1%)
|
120.89M
est: 178.75M (-32.4%)
|
197.47M
est: 173.78M (+13.6%)
|
176.56M
est: 191.16M (-7.6%)
|
145.35M
est: 189.51M (-23.3%)
|
156.77M
est: 161.12M (-2.7%)
|
140.73M
est: 987.09M (-85.7%)
|
1.07B
1.07B – 1.07B
+8.3% YoY
|
| Net Income |
261.85M
est: 272.09M (-3.8%)
|
3.18M
est: 310.25M (-99.0%)
|
85.55M
est: 78.32M (+9.2%)
|
95.12M
est: 102.41M (-7.1%)
|
113.86M
est: 122.16M (-6.8%)
|
94.80M
est: 86.35M (+9.8%)
|
202.22M
est: 178.72M (+13.2%)
|
181.79M
est: 203.82M (-10.8%)
|
115.78M
est: 198.80M (-41.8%)
|
128.00M
est: 105.02M (+21.9%)
|
163.04M
est: 660.15M (-75.3%)
|
739.17M
739.17M – 739.17M
+12.0% YoY
|
| SGA |
144.16M
est: 213.22M (-32.4%)
|
137.91M
est: 230.32M (-40.1%)
|
169.26M
est: 201.90M (-16.2%)
|
216.37M
est: 230.55M (-6.1%)
|
231.84M
est: 245.28M (-5.5%)
|
198.49M
est: 243.63M (-18.5%)
|
216.77M
est: 236.86M (-8.5%)
|
234.83M
est: 260.55M (-9.9%)
|
224.26M
est: 258.29M (-13.2%)
|
231.31M
est: 219.87M (+5.2%)
|
226.35M
est: 1.35B (-83.2%)
|
1.46B
1.46B – 1.46B
+8.3% YoY
|
| EPS |
2.66
est: 2.71 (-1.8%)
|
0.03
est: 3.09 (-99.0%)
|
0.86
est: 0.78 (+10.3%)
|
0.85
est: 1.02 (-16.7%)
|
1.14
est: 1.22 (-6.3%)
|
0.95
est: 0.86 (+10.5%)
|
2.03
est: 1.78 (+14.0%)
|
1.82
est: 2.03 (-10.3%)
|
1.16
est: 1.98 (-41.4%)
|
1.28
est: 1.05 (+21.9%)
|
1.63
est: 6.60 (-75.3%)
|
7.39
7.39 – 7.39
+12.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.00% | 12.2K | 0.65% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 1.9K | 0.42% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 21.0K | 0.46% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 81.0K | 0.39% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 3.8K | 0.44% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 48.6K | 0.28% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 30.4K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun Hui Wu | Vice President of Administration & Spokesman | — | — |
| Meng Wen Yang | Director | — | male |
| Yanshi Shen | Chairman, Chief Executive Officer & GM | — | — |
| Yingxiang Chu | Chief Financial Officer & Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1733.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
